World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery

Pfizer Inc.The World Bank and Pfizer Inc. announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa. The novel public-private collaboration will focus on enhanced use of Information and Communication Technologies' (ICT) transformative power to improve healthcare delivery. The project demonstrates both Pfizer's and the World Bank's commitment to improving healthcare delivery by creating a funding mechanism to expedite the identification of gaps in Africa's healthcare infrastructure and ultimately aid in the implementation of ICT solutions.

The effort will be part of the World Bank's new eTransform Initiative, which was formally launched at a World Bank Spring Meeting side event attended by developing country ministers of finance and communications. The eTransform Initiative aims to convene public and private sector stakeholders to promote government transformation through the use of innovative ICTs. The goal is to use technology to increase government effectiveness and help governments in developing countries use their healthcare and other resources more efficiently.

About 270 million people in Africa lack regular access to even the most essential medicines.(1) According to the World Health Organization (WHO), among the biggest obstacles to improved health outcomes are inadequate health delivery and financing mechanisms that place the heaviest burden on the poor and sick, who are the least able to pay.

"We recognize the importance of improving healthcare infrastructure in developing countries so more patients can have access to life-saving medicines," said Jean-Michel Halfon, president and general manager of Pfizer's Emerging Markets Business Unit. "This collaboration is the most recent example of Pfizer's Global Access strategy to improve healthcare access for low-income populations in emerging markets through non-traditional approaches that will contribute towards the development of commercially viable, sustainable delivery models."

The eTransform Initiative helps access global expertise through peer-to-peer networks of industry innovators and country leaders, and through a knowledge bank. It also establishes a mechanism to fast-track promising projects by funding their initial design. Under the eTransform Initiative, the World Bank and Pfizer will work together on knowledge-sharing initiatives. They will also work to set up a trust fund to finance innovative, ICT-based solutions to healthcare in developing countries.

The funding mechanism, or Healthcare Project Development Facility (HPDF), will be one of several sector-specific project development facilities within the eTransform Initiative. The HPDF entails that countries submit grant requests to support a competitively-bid feasibility study. Study outcomes serve as the basis for proposed solutions and, if accepted by the country and eligible for World Bank funding, the solution will be implemented on a country level.

The collaboration will focus on Africa in the initial phase. Africa is the world's fastest growing cellular market, with about 400 million mobile phones in use.(2) "With billions of people in the developing world having access to reliable technology, such as mobile communications, there is a tremendous opportunity to use technology to radically improve healthcare delivery," said Mohsen Khalil, director of the World Bank's Global Information and Communication Technologies Department. "Through public-private collaborations, which bring together global expertise, appropriate technologies, efficient processes, and necessary financial resources, the potential of health and technology can be fully realized."

The collaboration will focus on supporting the eTransform Initiative through studies or pilots that improve healthcare infrastructure and sharing global knowledge about technology in developing countries, including the use of mobile applications.

"We understand that to truly make a difference in the lives of low-income people in emerging markets, we first need research-based evidence to identify and better understand the existing capabilities and needs of a country to improve healthcare access for its people," said Ponni Subbiah, vice president, Pfizer Global Access.

about The World Bank
The World Bank is a multilateral development institution and one of the world's largest sources of financial and technical assistance to developing countries around the world. Comprised of 185 member governments, its primary focus is to help the world’s poorest people and the poorest countries. The World Bank uses its financial resources, its staff, and extensive experience to help developing countries reduce poverty, increase economic growth, and improve their quality of life. The World Bank is partnering with the ICT industry to leverage technology as an enabler in the context of the ICT Skills Development Initiative and the eTransform Initiative.

Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

1. BMJ 2005; 331:709-10.
2. "Africa: 448 million mobile network subscribers." Africa News. February 11, 2010.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]